FASLODEX J Code: J9395

Drug & Product Overview

HCPCS Descriptor Injection, fulvestrant, 25 mg

HCPCS Added Date January 1, 2004

Manufacturer Multiple Manufacturers

Route of Administration Intramuscular, Intravenous

Generic Status Multi-Source; Generic

Dosage Type Single-Dose

Dosage Form Injection | Injection, Solution | Not Available

About FASLODEX

Faslodex is a medication aligned to the HCPCS J Code: J9395 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intramuscular or intravenous routes and manufactured by multiple companies.

According to CMS Drug Use Information: Fulvestrant is used to treat certain types of breast cancer. Breast cancer cells need the hormone estrogen in order to grow. Fulvestrant works by blocking the effect of estrogen, slowing tumor cell growth.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. Showing 5 of 29 NDCs — log in for the full crosswalk.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
00143-9022-02	Fulvestrant	Hikma Pharmaceuticals USA Inc.	20	250 MG / 5 ML
00310-0720-10	Faslodex	AstraZeneca Pharmaceuticals LP	20	250 MG / 5 ML
00781-3532-12	Fulvestrant	Sandoz Inc	20	250 MG / 5 ML
16714-0070-02	Fulvestrant	Northstar Rx, LLC,	20	250 MG / 5 ML
16729-0436-30	Fulvestrant	Accord Healthcare Inc.	20	250 MG / 5 ML
•••••-••••-•• Log in to view	FASLODEX
	FASLODEX
	FASLODEX

Login to view 24 more NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

FASLODEX Pricing & Reimbursement

J9395 Private Payer Reimbursement

$6.02 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Fulvestrant 505(b)(2) Information:

HCPCS Code	Manufacturer	Active Ingredient	HCPCS Description
J9393	Avyxa Pharma	Fulvestrant	Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg
J9394	Fresenius Kabi	Fulvestrant	Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg
J9395	Generic Code (Multiple Manufacturers)	Fulvestrant	Injection, fulvestrant, 25 mg

FASLODEX CPT Administration Codes

CPT Code	Description
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Login for More	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) Login for More

JW / JZ modifiers apply

CMS has identified Faslodex (J9395) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

FASLODEX Medically Unlikely Edits (MUE)

The most billing units of J9395 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 25 mg.

Practitioner Office & Hospital Outpatient

20 units / day

= 500 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

FASLODEX Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

HR-positive advanced breast cancer HR-positive, HER2-negative advanced breast cancer HR-positive, HER2-negative advanced or metastatic breast cancer

Drug Class

Estrogen Receptor Antagonist [EPC]Estrogen Receptor Antagonists [MoA]Selective Estrogen Receptor Modulators [MoA]

Frequently Asked Questions

Is there an available Faslodex billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for FASLODEX.

Are there any available Faslodex patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for FASLODEX.

Where can I find Faslodex prescribing information?

FASLODEX prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date. Visit Here →

Where can I find Faslodex side effect information?

Our team has not yet identified a source of side effects information for FASLODEX. Please check back in a few weeks.

Does billing FASLODEX require JZ/JW wastage modifiers?

CMS has identified FASLODEX(J9395) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.